Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Bilastine 20 mg Orodispersible Tablet vs BILAXTEN 20 MG ODT under Fasting in Healthy Thai Volunteers
TCTR20260528001Phase 1Not yet recruiting
- Sponsor
- International Bio Service
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bilastine in allergic rhinitis (AR) and chronic idiopathic urticaria (CIU), sponsored by International Bio Service. Primary endpoint: Primary pharmacokinetic bioequivalence. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
bilastine
03
Conditions
allergic rhinitis (AR)chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on TCTR20260528001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260528001.